Erythropoietin (EPO), a haemopoietic growth factor and a primary regulator of erythropoiesis, is widely used to treat anaemia in various chronic complications of rheumatoid arthritis (RA). Fibroblast-like cells, found in the pannus tissue of joints, are thought to contribute to the inflammatory pathology of RA. Thus for the current study we investigated the effects of recombinant human EPO (rHuEPO) on NO metabolism, using an interleukin-lp (IL-la)-stimulated Swiss 3T3 fibroblast monolayer as a model for fibroblast activity in RA. The results show that, over 3 days, both alone and in combination with the pro-inflammatory cytokine I L -l p (1 0 ng/ml), rHuEPO (25 p-units/ml) induced significant production of nitrite in cell culture supernatants. This is an indicator of NO production by nitric oxide synthase (NOS), which is a well-documented mediator of metalloproteinase-mediated tissue remodelling in RA. It therefore appears that, through modulation of NOS-dependent NO production, rHuEPO may influence remodelling of connective tissue in RA, independently of its established erythropoietic role.
Introduction
Rheumatoid arthritis (RA) is a persistent autoimmune disease, involving chronic inflammation of the diarthroidal joints, which causes cartilage degradation and bone destruction [ 13. Synovial fibroblasts are a major component of rheumatoid pannus tissue, which on interaction with endothelial cells and macrophages produce chemical mediators, including NO, pro-inflammatory cytokines and matrix metalloproteinases [2] . These compounds function collectively to modulate inflammation and joint destruction in RA.
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NO is produced in response to inflammatory cytokines, particularly interleukin-lp (IL-la), tumour necrosis factor CI and interleukin-6 [3] , which are thought to contribute to the pathogenesis of anaemia of chronic disease (ACD), and is a common feature of RA [4] . Since NO is a free radical that is capable of oxidative pathology, the presence of nitrotyrosines in patients with RA is consistent with the formation of peroxynitrite in vivo [5] .
Erythropoietin (EPO), a 30.4 kDa haemopoietic growth factor, functions as a regulator of erythropoiesis [6] and is administered as therapy for the treatment of ACD in RA. At present little is known regarding the effect of recombinant human EPO (rHuEPO) on the inflammatory response associated with RA. Swiss 3T3 fibroblasts have been shown to produce NO when stimulated with the proinflammatory cytokine . Thus, this cell line was selected for the current investigation into the effect of rHuEPO on NO release in a model of rHuEPO therapy of RA.
Materials and methods

Chemicals and reagents
All chemicals, medium and sterile 24-and 96-well plates were purchased from Sigma-Aldrich, unless otherwise stated. I L -l p was from Peprotech EC.
Cell culture
Swiss 3T3 fibroblasts were grown to 80% confluence in a monolayer in complete supplemented medium prior to the addition of various single or combined treatments as follows : rHuEPO ( 6 1 0 0 p-units/ml) and/or IL-lp (0-20 ng/ml). T h e nitric oxide synthase (NOS) inhibitor N -( G ) -nitro-L-arginine methyl ester (L-NAME ; 100 pM) was applied in parallel to treatment groups as a control for NO production. T h e media and treatments were replenished every 24 h for up to 3 days. Media supernatants were stored in labelled Eppendorf microcentrifuge tubes at -20 "C until required for nitrite analysis. Cell viability was assessed using the Trypan Blue exclusion assay [8] and was found to be > 90% in all groups.
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Measurement of nitrite
Nitrite production was measured in cell culture media using the Griess reaction [9] . T h e absorbance was measured at 540 nm and the nitrite concentration was determined from a sodium nitrite standard curve. Nitrite was not detected either in media blanks incubated for 96 h or in media prior to cell culture.
Statistical analysis
Data were analysed and compared with controls using a two-tailed Student's t test. Significance was denoted as ++P < 0.01 or +++P < 0.001.
Results
Swiss 3 T 3 fibroblasts that had been exposed to 10 and 20 ng/ml IL-lD for 24 h produced between 1 and 2 pmol/ml nitrite, following 1, 2 and 3 days of culture. Peak nitrite production was measured on exposure to 10 ng/ml IL-lp after 1 day of culture (Figure 1 ). This treatment increased nitrite production by 300-400 '(, compared with untreated control cells ( P < 0.001). This effect was reduced to below the basal level of untreated cells following treatment with L-NAME (100 p M ) . Further evidence that rHuEPO induced N O production in fibroblasts is the observed increase in nitrite production by cells co-treated with IL-I/? and rHuEPO compared with cells treated with IL-1p alone. This increase was not statistically significant, but followed the same general pattern of an increase in nitrite production of 0.1-0.2pmol/ml after 1, 2 and 3 days of cell culture ( Figure 2, lower panel) . T h e magnitude of this response was comparable with that measured following treatment of cells with rHuEPO alone (Figure 2 , upper panel).
Discussion
IL-1p induces nitrite production, enhances the synthesis of human synovial fibroblasts and activates synoviocytes to synthesize and release collagenase, all modulators of matrix remodelling in RA [l] . Our findings show that, in a cell model of rHuEPO therapy of RA, direct exposure of Swiss 3 T 3 fibroblasts to 25 p-units/ml rHuEPO, either alone or in combination with IL-lp, induced a significant increase in nitrite production in the surrounding culture medium. Inhibition of nitrite production to below basal levels by L-NAME, a non-specific NOS inhibitor, showed that nitrite production was derived from N O S activation.
Several factors from this study support the hypothesis that the treatment of Swiss 3T3 fibro- 
